Home»Exposition»BerGenBio to Present Interim Clinical and Biomarker Data With Selective AXL Inhibitor Bemcentinib in AML and MDS at EHA

BerGenBio to Present Interim Clinical and Biomarker Data With Selective AXL Inhibitor Bemcentinib in AML and MDS at EHA

0
Shares
Pinterest Google+

BERGEN, Norway, May 18, 2018 /PRNewswire/ —
BerGenBio ASA (OSE: BGBIO) announces that the company and its collaborators will present interim clinical data from its Phase II clinical development programme with bemcentinib, a selective, oral AXL inhibitor, in acute myeloid leukaemia…

Previous post

International Day of Art of Giving Celebrated Across the World

Next post

Medical Robotic Systems Market to Become Worth US$ 25,738.8 Million by 2025, Says TMR